A Phase 2 interventional study of BGJ398 (infigratinib) in Advanced Cholangiocarcinoma and FGFR2 Gene Mutation, sponsored by QED Therapeutics, Inc.. Terminated at 37 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-03.
Sponsored by QED Therapeutics, Inc. (part of BridgeBio) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 111 under way, 7 of them phase 3. Cholangiocarcinoma · United States.
Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 59th largest by enrollment of the 279 interventional ones that give a count, is one of 18 that started in 2014, is one of 94 in phase 2, and was the 64th registered.
825 studies on the registry are indexed under Cholangiocarcinoma; 287 are open to participants now.
Browse Cholangiocarcinoma studies →72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:
Full-Life Technologies UK Limited · Sites in United States, Australia, China
Ages 18+
University of Pennsylvania · Sites in United States
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
328 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 127 · Phase 2 142 · Phase 3 24 · Phase 4 1
First in 2001; this study’s year is marked. 18 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 50 across 623 interventional studies indexed under Cholangiocarcinoma.
Median enrollment 44 across the 279 interventional studies, 230 across the 45 observational. Of the 190 that completed or were terminated, 94 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 328 have an industry lead sponsor. The 10 most frequent:
This study is registered under QED Therapeutics, Inc., one of the names counted as BridgeBio. Under that name alone:
QED Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
BridgeBio has 2 studies filed under Cholangiocarcinoma — fewer than ten, so there is no comparison to draw.
36 of the studies in Cholangiocarcinoma with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05948475Phase 3TransThera Sciences (Nanjing), Inc.Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | 2026-12 |
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT05506943Phase 3Compass TherapeuticsA Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | 2027-08-31 |
| NCT07265674Phase 3J-Pharma Co., Ltd.A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer | 2027-10 |
| NCT06723236MacroGenicsA Study of MGC028 in Participants With Advanced Solid Tumors | 2026-11 |
Add all 36 to your calendar (.ics) → With an account.
Among the 328 studies in Cholangiocarcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic alterations.
Adult patients with histologically or cytologically confirmed advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or translocations or other FGFR genetic alterations have been enrolled. Subjects must have received at least one prior regimen containing gemcitabine with or without cisplatin for advanced/metastatic disease. Subjects should have had evidence of progressive disease following their prior regimen or if prior treatment was discontinued due to toxicity must have continued evidence of measurable disease. Up to approximately 160 adult patients over age 18, both male and female were planned for enrollment.
Three cohorts of subjects comprise the study population:
Cohort 1: subjects with FGFR2 gene fusions (ie, fusions or rearrangements [formerly translocations]).
Cohort 2: subjects with FGFR genetic alterations other than FGFR2 gene fusions or rearrangements.
Cohort 3: subjects with FGFR2 gene fusions or rearrangements who have received a prior FGFR inhibitor.
All subjects received oral BGJ398 (infigratinib), once-daily, on a three weeks on (21 days), one week off (7 days) schedule. One treatment cycle consists of 28 days.
Notes:
Cohort 1 was pre-specified as the primary analysis population. Results of these analyses were previously disclosed (posted 22 June 2022). There were no additional efficacy or safety endpoints to assess in Cohort 1 after primary completion (01 March 2021).
Cohorts 2 and 3 were added at protocol amendment (PA) 4 to support only exploratory efficacy objectives of the study. These cohorts were ongoing the time of primary completion (01 March 2021). After interim review of the data from these cohorts (as permitted by the protocol) only limited efficacy was observed and the sponsor terminated the study early. Therefore, a formal efficacy analysis was not performed for Cohorts 2 and 3. However, baseline characteristics and safety data were analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with cancers of the gallbladder or ampulla of Vater are not eligible.
Exclusion criteria:
insufficient organ function
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To estimate the anti-tumor activity of BGJ398 (infigratinib)
Drug: BGJ398 (infigratinib)
Capsule for oral use
Overall Response Rate (ORR) as Assessed by Blinded Independent Central Imaging Review (BICR)
ORR is defined as the percentage (%) of subjects with a best overall response of Complete Response (CR) or Partial Response (PR), as per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions). Results were previously disclosed (22 June 2022). There are no additional efficacy endpoints to assess for Cohort 1, thus efficacy data were not re-analyzed for the final analysis. Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
Time frame: Analysis was conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Overall Response Rate (ORR) as Assessed by the Investigator
ORR is defined as the percentage (%) of subjects with a best overall response of CR or PR, evaluated by CT or MRI scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) only. These results were previously disclosed (22 June 2022). There are no additional efficacy endpoints to assess for Cohort 1, thus efficacy data were not re-analyzed for the final analysis. Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff for the primary analysis was 01 March 2021.
Best Overall Response (BOR)
BOR is defined as the best overall response a subject achieved during the study before any subsequent antineoplastic therapy. The endpoint is summarized for the rate of BOR of CR, PR, progressive disease (PD), and stable disease (SD), evaluated by CT or MRI scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. PD: at least a 20% increase in the sum of diameters of all target lesions from that of the smallest sum on study and an absolute increase in target lesion of at least 5mm. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusion)
Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Disease Control Rate (DCR)
DCR is the percentage (%) of subjects with a BOR of CR, PR, or SD, evaluated by CT or MRI scans every 28 days. Results are based on both BICR and on Investigator assessment. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). There are no additional efficacy endpoints to assess for Cohort 1, thus efficacy data were not re-analyzed for the final analysis. Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Progression-Free Survival (PFS)
PFS was calculated as the number of months from the first dose of study drug to the first documented progression or death due to any cause, whichever occurred earlier. Subjects without an assessment of progression or death were censored at the last adequate tumor assessment. For subjects who had an event after ≥2 missed visits, the subject was censored at the last adequate tumor assessment before the missing visit. Disease progression was assessed per RECIST (v1.1) and defined as at least a 20% increase in the sum of diameters of all target lesions from that of the smallest sum on study and an absolute increase in target lesion of at least 5mm. Results are based on both BICR and on Investigator assessment. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Overall Survival (OS)
OS was defined as the time (months) from the date of start of treatment to the date of death due to any cause. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Duration of Response (DOR)
DOR is defined as the time (months) from the initial response to the time of the event; defined as the first documented progression or death due to any cause, whichever was earlier. Note that results are based on a subgroup of subjects with confirmed responses (CR or PR) as assessed by BICR or by the Investigator. RECIST (v1.1) response criteria was as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Response Onset
Response onset was defined as the time (months) from the first study treatment administration date to the initial response. Note that results are based on a subgroup of subjects with confirmed responses (CR or PR) as assessed by BICR or by the Investigator. RECIST (v1.1) response criteria was as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Growth Modulation Index (GMI)
The GMI is defined as the ratio of PFS (months) during treatment with infigratinib relative to the time (months) to progression (TTP) during treatment with last prior line of therapy. Subjects served as their own control. Results are provided for both BICR and Investigator assessment. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
Time frame: Analysis conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Participants with a diagnosis of advanced or metastatic cholangiocarcinoma were recruited to this open-label, single-arm global study across 20 centers (9 in the US, 5 in W. Europe, 6 in Asia) based on documented evidence of FGFR gene alteration. The first participant was treated on 23 July 2014. The data cutoff for the primary analysis (Cohort 1 only) was 01 March 2021.The data cutoff for the final analysis (Cohort 2 and 3 only) was 07 February 2022.
| Milestone | Cohort 1: FGFR2 Fusions | Cohort 2: Other FGFR Alterations | Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor |
|---|---|---|---|
| Started | 108 | 25 | 10 |
| Treatment ongoing | 0 | 0 | 0 |
| Treatment ended | 108 | 25 | 10 |
| Completed | 108 | 25 | 10 |
| Not completed | 0 | 0 | 0 |
ORR is defined as the percentage (%) of subjects with a best overall response of Complete Response (CR) or Partial Response (PR), as per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions). Results were previously disclosed (22 June 2022). There are no additional efficacy endpoints to assess for Cohort 1, thus efficacy data were not re-analyzed for the final analysis. Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
| Percentage (%) of subjects with CR or PR | Cohort 1: FGFR2 Fusions |
|---|---|
| Overall Response Rate (ORR) as Assessed by Blinded Independent Central Imaging Review (BICR) | 23.1 (15.6 to 32.2) |
ORR is defined as the percentage (%) of subjects with a best overall response of CR or PR, evaluated by CT or MRI scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) only. These results were previously disclosed (22 June 2022). There are no additional efficacy endpoints to assess for Cohort 1, thus efficacy data were not re-analyzed for the final analysis. Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
| Percentage (%) of subjects with CR or PR | Cohort 1: FGFR2 Fusion/Rearrangements |
|---|---|
| Overall Response Rate (ORR) as Assessed by the Investigator | 32.4 (23.7 to 42.1) |
BOR is defined as the best overall response a subject achieved during the study before any subsequent antineoplastic therapy. The endpoint is summarized for the rate of BOR of CR, PR, progressive disease (PD), and stable disease (SD), evaluated by CT or MRI scans every 28 days. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. PD: at least a 20% increase in the sum of diameters of all target lesions from that of the smallest sum on study and an absolute increase in target lesion of at least 5mm. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusion)
| Participants | Cohort 1: FGFR2 Fusion/Rearrangements |
|---|---|
| BOR by BICR — Confirmed CR | 1 |
| BOR by BICR — Confirmed PR | 24 |
| BOR by BICR — Stable Disease | 66 |
| BOR by BICR — Progressive Disease | 11 |
| BOR by BICR — Not Done | 6 |
| BOR by Investigator — Confirmed CR | 0 |
| BOR by Investigator — Confirmed PR | 35 |
| BOR by Investigator — Stable Disease | 56 |
| BOR by Investigator — Progressive Disease | 11 |
| BOR by Investigator — Not Done | 6 |
DCR is the percentage (%) of subjects with a BOR of CR, PR, or SD, evaluated by CT or MRI scans every 28 days. Results are based on both BICR and on Investigator assessment. RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). There are no additional efficacy endpoints to assess for Cohort 1, thus efficacy data were not re-analyzed for the final analysis. Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
| Percentage (%) with CR, PR, or SD | Cohort 1: FGFR2 Fusion/Rearrangements |
|---|---|
| DCR by BICR | 84.3 (76.0 to 90.6) |
| DCR by Investigator | 84.3 (76.0 to 90.6) |
PFS was calculated as the number of months from the first dose of study drug to the first documented progression or death due to any cause, whichever occurred earlier. Subjects without an assessment of progression or death were censored at the last adequate tumor assessment. For subjects who had an event after ≥2 missed visits, the subject was censored at the last adequate tumor assessment before the missing visit. Disease progression was assessed per RECIST (v1.1) and defined as at least a 20% increase in the sum of diameters of all target lesions from that of the smallest sum on study and an absolute increase in target lesion of at least 5mm. Results are based on both BICR and on Investigator assessment. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
| months | Cohort 1: FGFR2 Fusion/Rearrangements |
|---|---|
| PFS by BICR | 7.29 (5.59 to 7.56) |
| PFS by Investigator | 6.74 (5.55 to 7.56) |
OS was defined as the time (months) from the date of start of treatment to the date of death due to any cause. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
| months | Cohort 1: FGFR2 Fusion/Rearrangements |
|---|---|
| Overall Survival (OS) | 11.86 (10.68 to 14.85) |
DOR is defined as the time (months) from the initial response to the time of the event; defined as the first documented progression or death due to any cause, whichever was earlier. Note that results are based on a subgroup of subjects with confirmed responses (CR or PR) as assessed by BICR or by the Investigator. RECIST (v1.1) response criteria was as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
| months | Cohort 1: FGFR2 Fusion/Rearrangements |
|---|---|
| DOR by BICR | 5.55 (3.78 to 7.66) |
| DOR by Investigator | 7.23 (5.16 to 9.00) |
Response onset was defined as the time (months) from the first study treatment administration date to the initial response. Note that results are based on a subgroup of subjects with confirmed responses (CR or PR) as assessed by BICR or by the Investigator. RECIST (v1.1) response criteria was as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
| months | Cohort 1: FGFR2 Fusion/Rearrangements |
|---|---|
| Response onset by BICR | 3.61 (1.38 to 7.36) |
| Response onset by Investigator | 1.94 (1.38 to 18.76) |
The GMI is defined as the ratio of PFS (months) during treatment with infigratinib relative to the time (months) to progression (TTP) during treatment with last prior line of therapy. Subjects served as their own control. Results are provided for both BICR and Investigator assessment. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
| Ratio (PFS/TTP) in Months | Cohort 1: FGFR2 Fusion/Rearrangements |
|---|---|
| PFS by BICR | 1.22 (0.00 to 120) |
| PFS by Investigator | 1.24 (0.00 to 120) |
Post-hoc subgroup assessment of efficacy in those subjects who were receiving infigratinib as a third or later line of treatment. Investigator-assessed ORR was obtained from subjects' medical histories to provide a baseline evaluation of their response after historical second-line antineoplastic treatment prior to infigratinib treatment. Investigator-assessed ORR was then calculated in the same subjects after third- or later-line infigratinib therapy. ORR is defined as the percentage (%) of patients with CR or PR, per RECIST (v1.1). RECIST (v1.1) response criteria were as follows: CR: disappearance of all target lesions. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease from baseline in the sum of diameters of all target lesions. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (22 June 2022). No formal efficacy analyses were performed for Cohorts 2 and 3.
| Percentage (%) of patients with CR or PR | Cohort 1: FGFR2 Fusion/Rearrangements |
|---|---|
| After Second-Line Therapy (Prior to Infigratinib Treatment) | 0 (0.0 to 6.1) |
| Third or Later-Line Therapy (Infigratinib) | 28.8 (17.8 to 42.1) |
Post-hoc subgroup assessment of efficacy in those subjects who were receiving infigratinib as a third or later line of treatment. Investigator-assessed PFS was obtained from subjects' medical histories to provide a baseline evaluation of their response after historical second-line antineoplastic treatment prior to infigratinib treatment. Investigator-assessed PFS was then calculated in the same subjects after third- or later-line infigratinib therapy. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
| months | Cohort 1: FGFR2 Fusion/Rearrangements |
|---|---|
| After Second-Line Therapy (Prior to Infigratinib Treatment) | 5.36 (3.25 to 8.15) |
| Third or Later-Line Therapy (Infigratinib) | 6.93 (4.76 to 7.59) |
Post-hoc subgroup assessment of efficacy in those subjects who were receiving infigratinib as a third or later line of treatment. Investigator-assessed BOR was obtained from subjects' medical histories to provide a baseline evaluation of their response after historical second-line antineoplastic treatment prior to infigratinib treatment. Investigator-assessed BOR was then calculated in the same subjects after third- or later-line infigratinib therapy. The endpoint is summarized for the rate of BOR of PD, SD, PR, and CR. Note: The primary efficacy outcome measures were prespecified only for Cohort 1 (FGFR fusions) (disclosed 22 June 2022). Due to early termination of the study, no formal efficacy analyses were performed for Cohorts 2 and 3.
| Participants | Cohort 1: FGFR2 Fusion/Rearrangements |
|---|---|
| After Second-Line Therapy (Prior to Infigratinib Treatment) — Complete response | 0 |
| After Second-Line Therapy (Prior to Infigratinib Treatment) — Partial response | 0 |
| After Second-Line Therapy (Prior to Infigratinib Treatment) — Stable disease | 19 |
| After Second-Line Therapy (Prior to Infigratinib Treatment) — Progressive disease | 22 |
| After Second-Line Therapy (Prior to Infigratinib Treatment) — Unknown | 18 |
| After Second-Line Therapy (Prior to Infigratinib Treatment) — Not done | 0 |
| Third or Later-Line Therapy (Infigratinib) — Complete response | 0 |
| Third or Later-Line Therapy (Infigratinib) — Partial response | 17 |
| Third or Later-Line Therapy (Infigratinib) — Stable disease | 31 |
| Third or Later-Line Therapy (Infigratinib) — Progressive disease | 7 |
| Third or Later-Line Therapy (Infigratinib) — Unknown | 0 |
| Third or Later-Line Therapy (Infigratinib) — Not done | 4 |
Collected over From first administration of infigratinib with follow-up of at least 10 months after initial exposure. Data cutoff for Cohort 1 (primary analysis population) was 01 March 2021 (disclosed 22 June 2022). Data cutoff for Cohorts 2 and 3 (exploratory analysis only) was 07 February 2022.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: FGFR2 Fusions | 93/108 (86.1%) | 35/108 (32.4%) | 107/108 (99.1%) |
| Cohort 2: Other FGFR Genetic Alterations | 19/25 (76%) | 11/25 (44%) | 25/25 (100%) |
| Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor | 7/10 (70%) | 2/10 (20%) | 10/10 (100%) |
| Event | Cohort 1: FGFR2 Fusions | Cohort 2: Other FGFR Genetic Alterations | Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor |
|---|---|---|---|
| AscitesGastrointestinal disorders | 2/108 | 0/25 | 1/10 |
| HypophosphataemiaMetabolism and nutrition disorders | 2/108 | 0/25 | 1/10 |
| NauseaGastrointestinal disorders | 0/108 | 0/25 | 1/10 |
| VomitingGastrointestinal disorders | 0/108 | 0/25 | 1/10 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/108 | 0/25 | 1/10 |
| PyrexiaGeneral disorders | 4/108 | 2/25 | 0/10 |
| Abdominal painGastrointestinal disorders | 2/108 | 1/25 | 0/10 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/108 | 1/25 | 0/10 |
| Intestinal ischaemiaGastrointestinal disorders | 0/108 | 1/25 | 0/10 |
| General physical health deteriorationGeneral disorders | 1/108 | 1/25 | 0/10 |
| Event | Cohort 1: FGFR2 Fusions | Cohort 2: Other FGFR Genetic Alterations | Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor |
|---|---|---|---|
| HyperphosphataemiaMetabolism and nutrition disorders | 83/108 | 23/25 | 7/10 |
| StomatitisGastrointestinal disorders | 59/108 | 13/25 | 7/10 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 19/108 | 5/25 | 6/10 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 37/108 | 6/25 | 5/10 |
| ConstipationGastrointestinal disorders | 34/108 | 11/25 | 3/10 |
| FatigueGeneral disorders | 44/108 | 10/25 | 3/10 |
| Dry eyeEye disorders | 39/108 | 3/25 | 4/10 |
| NauseaGastrointestinal disorders | 21/108 | 10/25 | 3/10 |
| AlopeciaSkin and subcutaneous tissue disorders | 43/108 | 9/25 | 1/10 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 35/108 | 4/25 | 1/10 |
Full Analysis Set (FAS), defined as all subjects who had received at least 1 dose of infigratinib.
| Age, Categorical(Participants) | Cohort 1: FGFR2 Fusions | Cohort 2: Other FGFR Genetic Alterations | Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 82 | 17 | 8 | 107 |
| >=65 years | 26 | 8 | 2 | 36 |
| Age, Continuous(years) | Cohort 1: FGFR2 Fusions | Cohort 2: Other FGFR Genetic Alterations | Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor | Total |
|---|---|---|---|---|
| Mean | 53.4 ± 13.08 | 59.9 ± 9.89 | 51.8 ± 12.07 | 54.0 ± 12.88 |
| Sex: Female, Male(Participants) | Cohort 1: FGFR2 Fusions | Cohort 2: Other FGFR Genetic Alterations | Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor | Total |
|---|---|---|---|---|
| Female | 67 | 12 | 3 | 82 |
| Male | 41 | 13 | 7 | 61 |
| Race (NIH/OMB)(Participants) | Cohort 1: FGFR2 Fusions | Cohort 2: Other FGFR Genetic Alterations | Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 11 | 2 | 0 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 1 | 2 | 7 |
| White | 78 | 22 | 8 | 108 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 15 | 0 | 0 | 15 |
| Region of Enrollment(Participants) | Cohort 1: FGFR2 Fusions | Cohort 2: Other FGFR Genetic Alterations | Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor | Total |
|---|---|---|---|---|
| North America | 77 | 12 | 5 | 94 |
| Europe | 24 | 11 | 5 | 40 |
| South Korea | 0 | 1 | 0 | 1 |
| Singapore | 4 | 0 | 0 | 4 |
| Taiwan | 1 | 0 | 0 | 1 |
| Thailand | 2 | 1 | 0 | 3 |
| ECOG PS(Participants) | Cohort 1: FGFR2 Fusions | Cohort 2: Other FGFR Genetic Alterations | Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor | Total |
|---|---|---|---|---|
| 0 | 45 | 11 | 3 | 59 |
| 1 | 62 | 13 | 7 | 82 |
| 2 | 1 | 1 | 0 | 2 |
| Primary site of cancer(Participants) | Cohort 1: FGFR2 Fusions | Cohort 2: Other FGFR Genetic Alterations | Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor | Total |
|---|---|---|---|---|
| Bile Duct | 105 | 24 | 10 | 139 |
| Cholangiocarcinoma | 1 | 1 | 0 | 2 |
| Liver | 2 | 0 | 0 | 2 |
| Non-Liver Metastatic Site(Participants) | Cohort 1: FGFR2 Fusions | Cohort 2: Other FGFR Genetic Alterations | Cohort 3: FGFR2 Fusions and Prior FGFR Inhibitor | Total |
|---|---|---|---|---|
| No metastatic site | 5 | 4 | 0 | 9 |
| Had metastatic site | 102 | 21 | 10 | 133 |
| Missing | 1 | 0 | 0 | 1 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2014 to primary completion in Mar 2021, 79 months.
Results were first posted in Jul 2022, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infigratinib